Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by John M. Goldman
EVI-1 Oncogene Expression Predicts Survival in Chronic-Phase CML Patients Resistant to Imatinib Treated With Second-Generation Tyrosine Kinase Inhibitors
Blood
Biochemistry
Immunology
Cell Biology
Hematology
ABL-BCR Expression Does Not Correlate With Deletions on the Derivative Chromosome 9 or Survival in Chronic Myeloid Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Related publications
Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
Oncology
Hematology
Arterial Events in Patients With Chronic Myeloid Leukemia Receiving Treatment With Second Generation Tyrosine Kinase Inhibitors
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Comment on "Second-Generation Tyrosine Kinase Inhibitors Improve the Survival of Patients With Chronic Myeloid Leukemia in Whom Imatinib Therapy Has Failed" Haematologica 2011;96(12):1779-82
Haematologica
Hematology
Cardiotoxicity Monitoring in Patients Treated With Tyrosine Kinase Inhibitors
Oncologist
Cancer Research
Medicine
Oncology
The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
Oncology
Hematology
Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Thyroid
Medicine
Endocrinology
Metabolism
Diabetes
Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase
Revista de Chimie
Surfaces
Materials Science
Engineering
Materials Chemistry
Films
Coatings
Chemistry
Overcoming Resistance to First/Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and ALK Inhibitors in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer
Therapeutic Advances in Medical Oncology
Oncology
